Merck & Co., Inc. 13D and 13G filings for Evaxion Biotech A/S:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-03 4:15 pm Purchase | 2025-01-31 | 13G | Evaxion Biotech A/S EVAX | Merck & Co. Inc. MRK | 63,004,142 19.960% | 61,460,024 (+3980.27%) | Filing |
| 2024-11-06 4:09 pm Purchase | 2024-09-30 | 13G | Evaxion Biotech A/S EVAX | Merck & Co. Inc. MRK | 1,544,118 12.900% | 625,000 (+68.00%) | Filing |
| 2024-01-23 3:29 pm Purchase | 2023-12-21 | 13G | Evaxion Biotech A/S EVAX | Merck & Co. Inc. MRK | 919,118 11.400% | 919,118 (New Position) | Filing |